anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method, communication system and computer program for providing information indicative of an allergen concentration in an environment are disclosed. A person detecting symptoms of dyspnea, possibly due to the presence of allergens in the environment, uses her/his mobile device to record information about the detected symptoms. The recording includes providing subjective information about the detected dyspnea symptom through a graphical interface of the mobile device. The mobile device uses the automatically generated objective information (date and time) to complete information about the detected symptoms. The mobile device then shares at least a portion of the recorded information related to the detected symptom on a sharing server. Any other mobile device may receive the shared portion of the recorded information related to the detected symptom from the shared server and display it on a map displayed by its display.
A system for use during a medical or surgical procedure on a body. The system generates a display representing the position of two or more body elements during the procedure based on an image data set generated by a scanner prior to the procedure. The image data set has reference points for each of the body elements, the reference points of a particular body element having a fixed spatial relation to the particular body element. The system includes an apparatus for identifying, during the procedure, the relative position of each of the reference points of each of the body elements to be displayed. The system also includes a processor for modifying the image data set according to the identified relative position of each of the reference points during the procedure, as identified by the identifying apparatus, said processor generating a displaced image data set representing the position of the body elements during the procedure. The system also includes a display utilizing the displaced image data set generated by the processor, illustrating the relative position of the body elements during the procedure. Methods relating to the system are also disclosed.
To compare the safety and effectiveness of the combination of intelligent intrarenal pressure control platforms and flexible end ureteral access sheath combined with flexible ureteroscopic lithotripsy (FURL) for the treatment of renal stones less than 2 cm with day case mode. From November 2023 to July 2024, a prospective, randomized, double-blind, parallel-controlled study was conducted to recruit 60 patients with upper urinary tract calculi measuring ≤ 2 cm in longest diameter. A total of 60 eligible patients were consecutively enrolled. Based on a pre-generated random number table and allocation scheme using SPSS 27.0, patients were assigned to either the intelligent pressure control group (IFURL, n = 30) or the head bending group (BFURL, n = 30). Blinding measures were implemented for patients, data collectors, statisticians, and analysts, with the allocation results disclosed to the surgeons prior to the start of the procedure in the operating room. The operation duration for IFURL and BFURL was 52.50 (48.00, 60.00) vs. 46.00 (36.00, 56.25), respectively (p = 0.047). Stone free rate (SFR) on the first postoperative day was 73.33% vs. 93.33% for IFURL and BFURL, respectively (p = 0.038). While, SFR was no significant difference between the two groups after two months(90.00% vs. 96.67%, p = 0.301). One patient in IFURL was readmitted after discharge due to fever 2 days post-discharge, and improved after 2 days of anti-infection treatment. One patient in BFURL was readmitted due to lumbar and abdominal pain from urine extravasation, which improved after 3 days of anti-infection treatment. SFR of one-month post-surgery for renal calculi ≤ 2 cm treated with intelligent pressure control and flexible UAS combined with FURL in day surgery mode was similar, with low infection-related complications and rehospitalization rates, showing no statistical difference. However, the overall hospitalization costs for the BFURL was lower than IFURL.
System of the present invention provide antipruritic (anti allergic), analgesic, anti-inflammatory, anti-cancer, mediating immunity and adjust the body organs of the drug. It also has to provide nutrition to strengthen the body's immune system and modulation method thereof and its use for food and drink and drugs for external use (coating film formulations. A kind of lactic acid bacteria as the effective components of the treatment: Natural antibiotics. Antifungal agents. Histamine. Glucocorticoid, In place of the glucocorticoid hormone, immunosuppressive agents, and immune modulators. Vitamin drugs. Biological agents are also considered to achieve prevention The effect of disease. Inhibition of tumor proliferation. In the gastrointestinal tract diseases, metabolic disorders, cardiovascular disease, cholesterol lowering effect, ease of lactose intolerance have a certain effect.
This non-inferiority randomized controlled clinical trial, with two parallel groups with 1:1 allocation ratio, was approved by the Research Ethics Committee of Universidade Ibirapuera (UNIB). The other centers involved are considered co-participants (Centro Universitário do Norte - Uninorte , Centro Universitário Uninovafapi - UNINOVAFAPI, and School of Dentistry from the University of Sao Paulo - FOUSP). Children aged 3 to 6 years with at least one proximal cavitated lesion on anterior primary teeth will be selected from the Clinical Pediatric Research Center. Teeth will be randomly allocated to selective removal of carious tissue and resin composite restoration (RCR) or NRCC. Tooth survival after two years of follow-up will be the primary outcome and cost-effectiveness, satisfaction, and discomfort reported by participants and parents/guardians' perception will be the secondary outcomes. Only patients who fulfill the eligibility criteria will be included in the study after the legal guardians sign the informed consent form and the child consents to participate in the study.
Most children with acute hepatitis A virus (HAV) or hepatitis E virus (HEV) infection are asymptomatic. Bystander CD8+ T-cell activation has garnered attention owing to its possible pathophysiological role in adult hepatitis. However, no reports have studied it in pediatric hepatitis. Herein, we describe the case of a three-year-old girl with acute hepatitis by HEV genotype 1. She had a history of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, and HEV hepatitis occurred shortly after asymptomatic HAV infection. Peripheral immunophenotyping revealed activation of non-HEV-specific CD8+ T cells which include EBV-specific and CMV-specific CD8+ T cells, during the acute phase. While alanine-aminotransferase levels declined after admission, the total number of activated CD8+ T cells increased for four days after admission and decreased thereafter. In contrast, activation of EBV-specific and CMV-specific CD8+ T cells was almost at the maximal level at the time of admission, which suggest development of activated bystander CD8+ T cells in the early stage. This case highlights the significance of the bystander CD8+ T-cell activation even in pediatric hepatitis and the size of the CD8+ T cell memory pool in the individuals for the development of hepatitis, given the patient's history of infections with EBV, CMV and HAV.
The study will be a randomised, single-blind (sponsor-unblinded), placebo-controlled, study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of repeat intravenous infusions (2 doses 4-weeks apart) of GSK1070806 in obese patients with T2DM. The primary objective of the study will be to assess improvements in fasting and postprandial glucose control. This will be a parallel-group study in 30 obese subjects with T2DM who are poorly controlled on metformin monotherapy (HbA1C\>7% but \<9.5%), and who have levels of microalbuminuria indicative of progressive kidney disease i.e. 30-300mg/L albumin in urine or ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤30mg/mmol. There will be three treatment groups comprising two active and one placebo arm with 10 subjects per dose group. The study contains a broad range of biomarker assessments, the purpose of which is to evaluate the mechanistic basis by which GSK1070806 exerts its therapeutic benefit in subjects with T2DM.

Subjects will be randomised into one of the three treatment groups where they will receive two intravenous infusions of GSK1070806 or placebo twenty-eight days apart. A MMT challenge will be conducted on Day 1, Day 29, Day 57 and Day 85 for evaluation of the primary endpoints.
Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
The goal of this project is to complete development of a unique thin film technology to be used as a skin barrier underneath surgical and examination gloves. The technology, which is antimicrobial upon application to skin, has been developed to reduce transmission of bacteria and bloodborne pathogens, and is expected to protect skin from the detrimental effects of chronic glove occlusion and hand washing. Due to the increased prevalence of human immunodeficiency virus (HIV) and hepatitis, the efficacy of surgical and examination gloves has become an important safety issue, especially for health care workers where occupational exposure to pathogens in blood or other body fluids is common. Transmission can occur from both caregiver to patient, and from patient to caregiver. However, glove leaks are frequent and the potential for pathogen transmission is of great concern. In addition, as awareness of the hazards from bloodborne pathogen transmission increased along with AIDS awareness in the 1990s, the concomitant increased use of disposable gloves has adversely affected skin condition, causing increased cumulative irritation contact dermatitis and heightened dermal sensitization to natural rubber latex. This unique thin film technology is a blend of polyvinylidene fluoride (PVDF) and acrylic polymers that forms thin membrane coatings that provide a tough, flexible barrier to liquids, yet have a "breathable" microporous structure. PVDF-based coatings are applied as a fast drying liquid solution that casts an adherent contiguous film directly on the skin upon drying. The liquid solution is antimicrobial on contact, and after drying, the coatings are durable, resistant to penetration by pathogens, and stay intact for 8 hours or longer. Phase I studies established the feasibility of using the PVDF technology as a protective barrier to be worn underneath gloves. The Phase I studies focused on exploiting the coating's inherent hydrophobicity to create a barrier to bacterial and viral penetration while maintaining breathability and comfort. The coatings demonstrated barrier function to viral and bacterial pathogens in vitro, proved to be safe in animal safety studies, and were shown to be a barrier to liquid in human trials. Phase II studies will complete the development of the PVDF technology for use as a novel protective underglove. The following aims have been designed to demonstrate safety and efficacy of the product and to satisfy Food and Drug Administration (FDA) requirements: implement Good Manufacturing Practices (GMP) and establish packaging; evaluate coating formulations in human subjects for effects on skin physiology; and demonstrate safety of coatings in human studies. A skin coating to be worn under gloves that is antimicrobial on contact, provides a barrier to bloodborne and bacterial pathogens, is a barrier to latex proteins, and could improve skin conditions on hands, would be beneficial to healthcare in the workplace and likewise have significant commercial potential.
The students in the experimental group will receive a new teaching method of five scenario-based case videos. These scenarios include Triage, SDH (Subdural Hemorrhage) and ETTC (Emergency Trauma Training Course), AMI (Acute Myocardial Infarction) and D2B (Door to Balloon), COPD AE (Chronic Obstructive Pulmonary Disease with Acute Exacerbation) and TOCC (Travel, Occupation, Contact, and Cluster History Review), and Sepsis and CVC Procedure (Central Venous Catheter Procedure).
INTRODUCTION: Autologous costal cartilage harvest is a common procedure in craniofacial reconstruction due to its stability, dependability, and diversity. However, such a procedure is associated with severe donor-site pain postoperatively. Therefore, we aim through this study to compare the efficacy of intercostal nerve block in the management of postoperative pain in patients undergoing costal cartilage harvest for craniofacial reconstruction.
METHOD: This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. The study systematically reviewed MEDLINE, Cochrane, and EMBASE databases without time-limitation.
RESULTS: As a result of reviewing the literature, 33 articles were screened by full-text resulting in 14 articles which met our inclusion/exclusion criteria. However, only four high-quality RCT articles were included in the quantitative synthesis (meta-analysis). The findings of this study suggest that there is no significant difference in pain scores between ICNB and control groups at 12, 24, and 48 h postoperatively, both at rest and with coughing. Therefore, both techniques are considered safe and effective.
CONCLUSION: Our results show evidence of favorable outcome of preventive donor-site analgesia with ICNB for harvesting autologous costal cartilage in multiple studies. However, the overall outcomes were insignificant between the two arms.
NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Intestinal ischemia-reperfusion (IR) injury is a common gastrointestinal disease that induces severe intestinal dysfunction. Intestinal myenteric neurons participate in maintaining the intestinal function, which will be severely injured by IR. Macrophages are widely reported to be involved in the pathogenesis of organ IR injury, including intestine, which is activated by NLRP3 signaling. Lonicerin (LCR) is a natural extracted monomer with inhibitory efficacy against the NLRP3 pathway in macrophages. The present study aims to explore the potential protective function of LCR in intestinal IR injury. Myenteric neurons were extracted from mice. RAW 264.7 cells were stimulated by H/R with or without 10 μM and 30 μM LCR. Remarkable increased release of IL-6, MCP-1, and TNF-α were observed in H/R treated RAW 264.7 cells, along with an upregulation of NLRP3, cleaved-caspase-1, IL-1β, and EZH2, which were sharply repressed by LCR. Myenteric neurons were cultured with the supernatant collected from each group. Markedly decreased neuron number and shortened length of neuron axon were observed in the H/R group, which were signally reversed by LCR. RAW 264.7 cells were stimulated by H/R, followed by incubated with 30 μM LCR with or without pcDNA3.1-EZH2. The inhibition of LCR on NLRP3 signaling in H/R treated RAW 264.7 cells was abolished by EZH2 overexpression. Furthermore, the impact of LCR on neuron number and neuron axon length in myenteric neurons in the H/R group was abated by EZH2 overexpression. Collectively, LCR alleviated intestinal myenteric neuron injury induced by H/R treated macrophages via downregulating EZH2.
Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR.
Porous semi-permeable artificial self-attaching scab designed to protect the eroded or injured surfaces. It can be applied on any living being (including plants). The polymerized mesh of the scab is formed when applied on the injured area by a process in which the lysed cells release enzymes that catalyze the reaction. Under this protective surface, the growth of new normal cells that can breathe freely without drying up is promoted. As a result, loss of water, proteins and electrolytes can be avoided; infections can be prevented; and the use of dressing and gauze bandage can be eliminated since they harm the new skin removed. The aqueous thixotropic red-colored fluid applied by brushing or spraying was obtained as a result of the reaction occurred in the container by the combination of the following substances: azosulfamide 1% to 5%+gentian violet 0.004% to 0.007%+dexamethasone 0.001% to 0.003′%+pantothenyl alcohol 0.5% to 2%+gentamicin 0.03% to 0.06%.
A milk-protein hydrolyzate consisting of a mixture of peptides and free amino acids having proliferation activating property on human cutaneous cells but not having antigenicity of the milk-protein may be obtained by enzymatic hydrolysis of milk protein. The peptides of the hydrolyzate have molecular weights less than 1000 daltons, and the hydrolyzate has a free aromatic amino acid/total aromatic amino acid ratio of at least 90%. Fractionation of the milk protein hydrolyzate yields a fraction consisting of a mixture of peptides. The fraction has a proliferation activating property on human cutaneous cells but does not have the antigenicity of the milk protein. The fraction contains aromatic amino acids in an amount of less than 5% by weight of total amino acids. Both the hydrolyzate and the fraction can be formulated into cosmetic compositions for application to the hair and skin.
Adults between the ages of 18 and 60 were recruited and randomly assigned to the treatment group and waitlist group in the ratio of 2:1. Based on the screening results, 75 participants were assigned to each of the four intervention programs within MINDLiNG (Riggy, Pleaser, Shelly, and Jumpy).
Treatment group receives pre-determined massage therapy protocol x 5 over 10-12 weeks. massage therapy protocol includes a blend of Swedish strokes and myofascial trigger point therapy. Initially, dosing will be more frequent. Treatments will be spaced out to determine the ability of the body to maintain a more efficient musculoskeletal system, especially related to respiratory and postural efforts. Each session will end with resting hands and relaxation strokes to signal the end of the session. This protocol invites increased mobility in the musculoskeletal system. The ultimate goal is to return connective tissue (including muscles and fascia) to a more relaxed and neutral state, thus allowing expansion and ease of movement of the areas of the musculoskeletal system being worked.
The addictive use of nicotine contained in tobacco is associated with stressor-like emotional and cognitive effects such as anxiety and working memory impairment, and the involvement of epigenetic mechanisms such as histone acetylation has recently been reported. Although the precise nature of behavioural plasticity remains unclear, both anxiogenic- and working memory impairment-like effects were observed in the present experimental model of mice treated with repeated subcutaneous nicotine and/or immobilization stress, and these effects were commonly attenuated by the histone deacetylase (HDAC) inhibitors that induce histone acetylation. Such HDAC inhibitor-induced resilience was mimicked by ligands for the endocannabinoid (ECB) system, a neurotransmitter system that is closely associated with nicotine-induced addiction-related behaviours: the anxiogenic-like effects were mitigated by the cannabinoid type 1 (CB1) agonist arachidonylcyclopropylamide (ACPA), whereas the working memory impairment-like effects were mitigated by the CB1 antagonist SR 141716A. Moreover, the effects of the HDAC inhibitors were also mimicked by ligands for the endovanilloid (transient receptor potential vanilloid 1 [TRPV1]) system, a system that shares common characteristics with the ECB system: the anxiogenic-like effects were mitigated by the TRPV1 antagonist capsazepine, whereas the working memory impairment-like effects were mitigated by the TRPV1 agonist olvanil. Notably, the HDAC inhibitor-induced anxiolytic-like effects were attenuated by SR 141716A, which were further counteracted by capsazepine, whereas the working memory improvement-like effects were attenuated by capsazepine, which were further counteracted by SR 141716A. These results suggest the contribution of interrelated control of the ECB/TRPV1 systems and epigenetic processes such as histone acetylation to novel therapeutic approaches.
PROBLEM TO BE SOLVED: To obtain a new vector for the formation of heterologous antibodies useful in, e.g. diagnoses/therapies, by making the vector include a DNA sequence homologous with a part of the endogenous immunoglobulin gene locus of a non-primate mammal and then introducing a fault, through homologous recombination, into a part of the invariant domain of the gene locus. SOLUTION: This new inactivated vector, which is intended to deactivate the endogenous immunoglobulin gene locus of a non-primate mammal, is obtained by including a DNA sequence homologous with part of the endogenous immunoglobulin gene locus of the non-primate mammal and then introducing a disorder, through the homologous recombination between the DNA sequence and the endogenous immunoglobulin gene locus of a non-primate mammal, into at least part of the invariant (C) domain of the above gene locus. Thus vector is useful e.g. for preparing a transgenic non-primate mammal having the ability to produce human immunoglobulin usable in, e.g. treating human diseases by making a non-primate mammal lase the endogenous immunoglobulin productivity followed by transferring human immunoglobulin gene into the mammal.
Iridocyclitis and the use of glucocorticoid medication have been widely studied as susceptibility factors for cataracts. However, the causal relationship between them remains unclear. This study aimed to investigate the causal relationship between the development of iridocyclitis and the genetic liability of glucocorticoid medication use on the risk of senile cataracts occurrence by performing Two-sample Mendelian randomization (MR) analyses. Instrumental variables (IVs) significantly associated with exposure factors (P < 5 × 10-8) were identified using published genome-wide association data from the FinnGen database and UK Biobank. Reliability analyses were conducted using five approaches, including inverse-variance weighted (IVW), MR-Egger regression, simple median, weighted median, and weighted mode. A sensitivity analysis using the leave-one-out method was also performed. Genetic susceptibility to glucocorticoid use was associated with an increased risk of developing senile cataracts (OR, 1.10; 95% CI, 1.02-1.17; P < 0.05). Moreover, iridocyclitis was significantly associated with a higher risk of developing senile cataracts (OR, 1.03; 95% CI, 1.01-1.05; P < 0.05). Nonetheless, some heterogeneity in the IVs was observed, but the MR results remained consistent after penalizing for outliers. The estimates were consistent in multivariate analyses by adjusting for body mass index (BMI) and diabetes mellitus type 2 (T2DM). This study provides new insights into the prevention and management of senile cataracts by highlighting the increased risk associated with iridocyclitis and the use of glucocorticoids.